Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function.

Principe DR, Diaz AM, Torres C, Mangan RJ, DeCant B, McKinney R, Tsao MS, Lowy A, Munshi HG, Jung B, Grippo PJ.

Oncogene. 2017 Jul 27;36(30):4336-4348. doi: 10.1038/onc.2016.500. Epub 2017 Apr 3.

2.

BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.

Kumar K, DeCant BT, Grippo PJ, Hwang RF, Bentrem DJ, Ebine K, Munshi HG.

JCI Insight. 2017 Feb 9;2(3):e88032. doi: 10.1172/jci.insight.88032.

3.

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.

Abedin SM, Boddy CS, Munshi HG.

Onco Targets Ther. 2016 Sep 28;9:5943-5953. eCollection 2016. Review.

4.

Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia.

Ebine K, Chow CR, DeCant BT, Hattaway HZ, Grippo PJ, Kumar K, Munshi HG.

Sci Rep. 2016 Jul 1;6:29133. doi: 10.1038/srep29133.

5.

Interaction of tRNA with MEK2 in pancreatic cancer cells.

Wang X, Chow CR, Ebine K, Lee J, Rosner MR, Pan T, Munshi HG.

Sci Rep. 2016 Jun 15;6:28260. doi: 10.1038/srep28260.

6.

Targeting BET bromodomain proteins in solid tumors.

Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG.

Oncotarget. 2016 Aug 16;7(33):53997-54009. doi: 10.18632/oncotarget.9804. Review.

7.

Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation.

Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, Jung B.

Oncotarget. 2017 Jan 17;8(3):3826-3839. doi: 10.18632/oncotarget.9830.

8.

PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction.

Principe DR, DeCant B, Diaz AM, Mangan RJ, Hwang R, Lowy A, Shetuni BB, Sreekumar BK, Chung C, Bentrem DJ, Munshi HG, Jung B, Grippo PJ, Bishehsari F.

Oncotarget. 2016 May 10;7(19):28218-34. doi: 10.18632/oncotarget.8587.

9.

TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis.

Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ.

Cancer Res. 2016 May 1;76(9):2525-39. doi: 10.1158/0008-5472.CAN-15-1293. Epub 2016 Mar 15.

10.

Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.

Kumar K, Chow CR, Ebine K, Arslan AD, Kwok B, Bentrem DJ, Eckerdt FD, Platanias LC, Munshi HG.

Mol Cancer Res. 2016 Feb;14(2):216-27. doi: 10.1158/1541-7786.MCR-15-0285. Epub 2015 Nov 25.

11.

Cancer Cell Invasion in Three-dimensional Collagen Is Regulated Differentially by Gα13 Protein and Discoidin Domain Receptor 1-Par3 Protein Signaling.

Chow CR, Ebine K, Knab LM, Bentrem DJ, Kumar K, Munshi HG.

J Biol Chem. 2016 Jan 22;291(4):1605-18. doi: 10.1074/jbc.M115.669606. Epub 2015 Nov 20.

12.

Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.

Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC.

Mol Cell Biol. 2015 Aug;35(15):2684-98. doi: 10.1128/MCB.00019-15. Epub 2015 May 26.

13.

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.

Kumar K, Raza SS, Knab LM, Chow CR, Kwok B, Bentrem DJ, Popovic R, Ebine K, Licht JD, Munshi HG.

Sci Rep. 2015 Mar 25;5:9489. doi: 10.1038/srep09489.

14.

Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.

Gounaris E, Heiferman MJ, Heiferman JR, Shrivastav M, Vitello D, Blatner NR, Knab LM, Phillips JD, Cheon EC, Grippo PJ, Khazaie K, Munshi HG, Bentrem DJ.

PLoS One. 2015 Mar 6;10(3):e0121402. doi: 10.1371/journal.pone.0121402. eCollection 2015.

15.

Comparative effectiveness in esophagogastric cancer.

Knab LM, Belotte J, Munshi HG, Bentrem DJ.

Cancer Treat Res. 2015;164:121-42. doi: 10.1007/978-3-319-12553-4_8.

PMID:
25677022
16.

Ablation of 5-lipoxygenase mitigates pancreatic lesion development.

Knab LM, Schultz M, Principe DR, Mascarinas WE, Gounaris E, Munshi HG, Grippo PJ, Bentrem DJ.

J Surg Res. 2015 Apr;194(2):481-7. doi: 10.1016/j.jss.2014.10.021. Epub 2014 Oct 22.

17.

Snail cooperates with Kras G12D in vivo to increase stem cell factor and enhance mast cell infiltration.

Knab LM, Ebine K, Chow CR, Raza SS, Sahai V, Patel AP, Kumar K, Bentrem DJ, Grippo PJ, Munshi HG.

Mol Cancer Res. 2014 Oct;12(10):1440-8. doi: 10.1158/1541-7786.MCR-14-0111. Epub 2014 Jun 18.

18.

BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.

Sahai V, Kumar K, Knab LM, Chow CR, Raza SS, Bentrem DJ, Ebine K, Munshi HG.

Mol Cancer Ther. 2014 Jul;13(7):1907-17. doi: 10.1158/1535-7163.MCT-13-0925. Epub 2014 May 7.

19.

TGF-β: duality of function between tumor prevention and carcinogenesis.

Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ.

J Natl Cancer Inst. 2014 Feb;106(2):djt369. doi: 10.1093/jnci/djt369. Review.

20.

Snail cooperates with KrasG12D to promote pancreatic fibrosis.

Shields MA, Ebine K, Sahai V, Kumar K, Siddiqui K, Hwang RF, Grippo PJ, Munshi HG.

Mol Cancer Res. 2013 Sep;11(9):1078-87. doi: 10.1158/1541-7786.MCR-12-0637. Epub 2013 Jun 12.

21.

Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.

Dangi-Garimella S, Sahai V, Ebine K, Kumar K, Munshi HG.

PLoS One. 2013 May 16;8(5):e64566. doi: 10.1371/journal.pone.0064566. Print 2013.

22.

Epithelial-mesenchymal transition and pancreatic cancer progression.

Dangi-Garimella S, Krantz SB, Shields MA, Grippo PJ, Munshi HG.

In: Grippo PJ, Munshi HG, editors. Pancreatic Cancer and Tumor Microenvironment. Trivandrum (India): Transworld Research Network; 2012. Chapter 5.

23.

Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.

Grippo PJ, Fitchev PS, Bentrem DJ, Melstrom LG, Dangi-Garimella S, Krantz SB, Heiferman MJ, Chung C, Adrian K, Cornwell ML, Flesche JB, Rao SM, Talamonti MS, Munshi HG, Crawford SE.

Gut. 2012 Oct;61(10):1454-64. doi: 10.1136/gutjnl-2011-300821. Epub 2012 Jan 10.

PMID:
22234980
24.

Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins.

Shields MA, Krantz SB, Bentrem DJ, Dangi-Garimella S, Munshi HG.

J Biol Chem. 2012 Feb 24;287(9):6218-29. doi: 10.1074/jbc.M111.308940. Epub 2012 Jan 9.

25.

Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression.

Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG.

Biochem J. 2012 Jan 15;441(2):541-52. doi: 10.1042/BJ20111240. Review.

PMID:
22187935
26.

Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression.

Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ.

J Surg Res. 2012 Mar;173(1):105-12. doi: 10.1016/j.jss.2011.09.020. Epub 2011 Oct 8. Review.

27.

Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.

Kircher SM, Krantz SB, Nimeiri HS, Mulcahy MF, Munshi HG, Benson AB 3rd.

Expert Rev Anticancer Ther. 2011 Oct;11(10):1555-65. doi: 10.1586/era.11.125. Review.

PMID:
21999129
28.

MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.

Krantz SB, Shields MA, Dangi-Garimella S, Cheon EC, Barron MR, Hwang RF, Rao MS, Grippo PJ, Bentrem DJ, Munshi HG.

Mol Cancer Res. 2011 Oct;9(10):1294-304. doi: 10.1158/1541-7786.MCR-11-0023. Epub 2011 Aug 19.

29.

Ethanol differentially regulates snail family of transcription factors and invasion of premalignant and malignant pancreatic ductal cells.

Ward ST, Dangi-Garimella S, Shields MA, Collander BA, Siddiqui MA, Krantz SB, Munshi HG.

J Cell Biochem. 2011 Oct;112(10):2966-73. doi: 10.1002/jcb.23215.

30.

Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion.

Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG.

J Biol Chem. 2011 Mar 25;286(12):10495-504. doi: 10.1074/jbc.M110.195628. Epub 2011 Feb 2.

31.

Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice.

Cheon EC, Khazaie K, Khan MW, Strouch MJ, Krantz SB, Phillips J, Blatner NR, Hix LM, Zhang M, Dennis KL, Salabat MR, Heiferman M, Grippo PJ, Munshi HG, Gounaris E, Bentrem DJ.

Cancer Res. 2011 Mar 1;71(5):1627-36. doi: 10.1158/0008-5472.CAN-10-1923. Epub 2011 Jan 7.

32.

Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.

Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ, Munshi HG.

Cancer Res. 2011 Feb 1;71(3):1019-28. doi: 10.1158/0008-5472.CAN-10-1855. Epub 2010 Dec 8.

33.

Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression.

Dangi-Garimella S, Strouch MJ, Grippo PJ, Bentrem DJ, Munshi HG.

Oncogene. 2011 Feb 24;30(8):1002-8. doi: 10.1038/onc.2010.485. Epub 2010 Nov 8.

34.

Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells.

Katsoulidis E, Mavrommatis E, Woodard J, Shields MA, Sassano A, Carayol N, Sawicki KT, Munshi HG, Platanias LC.

J Biol Chem. 2010 Dec 17;285(51):40333-41. doi: 10.1074/jbc.M110.151076. Epub 2010 Oct 18.

35.

Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.

Redig AJ, Munshi HG.

Oncology (Williston Park). 2010 Aug;24(9):839-44. Review.

36.

Rho-ROCK-myosin signaling mediates membrane type 1 matrix metalloproteinase-induced cellular aggregation of keratinocytes.

Dangi-Garimella S, Redig AJ, Shields MA, Siddiqui MA, Munshi HG.

J Biol Chem. 2010 Sep 3;285(36):28363-72. doi: 10.1074/jbc.M110.146019. Epub 2010 Jul 6.

37.

Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.

Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, Dangi-Garimella S, Wang E, Munshi HG, Khazaie K, Bentrem DJ.

Clin Cancer Res. 2010 Apr 15;16(8):2257-65. doi: 10.1158/1078-0432.CCR-09-1230. Epub 2010 Apr 6.

38.

Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.

Redig AJ, Munshi HG.

Am J Med. 2010 Jan;123(1):87.e1-6. doi: 10.1016/j.amjmed.2009.06.022. Review.

39.

Contribution of epithelial-mesenchymal transition to pancreatic cancer progression.

Krantz SB, Shields MA, Dangi-Garimella S, Bentrem DJ, Munshi HG.

Cancers (Basel). 2010 Dec 9;2(4):2084-97. doi: 10.3390/cancers2042084.

40.

Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination.

Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS.

Cancer Res. 2009 Sep 1;69(17):7121-9. doi: 10.1158/0008-5472.CAN-08-4151. Epub 2009 Aug 25.

41.

Slug is a downstream mediator of transforming growth factor-beta1-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells.

Joseph MJ, Dangi-Garimella S, Shields MA, Diamond ME, Sun L, Koblinski JE, Munshi HG.

J Cell Biochem. 2009 Oct 15;108(3):726-36. doi: 10.1002/jcb.22309.

PMID:
19681038
42.

Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen.

Moss NM, Liu Y, Johnson JJ, Debiase P, Jones J, Hudson LG, Munshi HG, Stack MS.

Mol Cancer Res. 2009 Jun;7(6):809-20. doi: 10.1158/1541-7786.MCR-08-0571. Epub 2009 Jun 9.

43.

Modulation of the membrane type 1 matrix metalloproteinase cytoplasmic tail enhances tumor cell invasion and proliferation in three-dimensional collagen matrices.

Moss NM, Wu YI, Liu Y, Munshi HG, Stack MS.

J Biol Chem. 2009 Jul 24;284(30):19791-9. doi: 10.1074/jbc.M109.020362. Epub 2009 May 19.

44.

Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.

Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL.

Cancer. 2008 Sep 15;113(6):1446-52. doi: 10.1002/cncr.23714. Erratum in: Cancer. 2009 Jun 15;115(12):2805. Patel, Urjeet [added].

45.

Differential growth factor regulation of N-cadherin expression and motility in normal and malignant oral epithelium.

Diamond ME, Sun L, Ottaviano AJ, Joseph MJ, Munshi HG.

J Cell Sci. 2008 Jul 1;121(Pt 13):2197-207. doi: 10.1242/jcs.021782. Epub 2008 Jun 10.

46.

Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression.

Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V, Munshi HG.

Mol Cancer Res. 2008 Jan;6(1):10-20. doi: 10.1158/1541-7786.MCR-07-0208.

47.

Activation-coupled membrane-type 1 matrix metalloproteinase membrane trafficking.

Wu YI, Munshi HG, Snipas SJ, Salvesen GS, Fridman R, Stack MS.

Biochem J. 2007 Oct 15;407(2):171-7.

48.

Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.

Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST.

Mol Cancer Ther. 2006 Jul;5(7):1783-9.

49.
50.

Reciprocal interactions between adhesion receptor signaling and MMP regulation.

Munshi HG, Stack MS.

Cancer Metastasis Rev. 2006 Mar;25(1):45-56. Review.

PMID:
16680571

Supplemental Content

Loading ...
Support Center